TICKERNOMICS Sign up
Last Update: 2023-12-23 06:03:42
Alaunos Therapeutics Inc. ( TCRT ) https://www.alaunos.com
0.05USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-91.78%
TCRT
SPY
30.72%
-98.33%
TCRT
SPY
112.82%
-97.54%
TCRT
SPY
201.04%
-98.87%
TCRT
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
11.64
-0.30
2.58
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.32
3.79
0.84
-251.00
0.00
0.01
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-216600.00
100.00
-109113.33
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.7294
-48.75
-58.50
0.21
Other Earnings and Cash Flow Stats:
Alaunos Therapeutics Inc. ( TCRT ) Net Income TTM ($MM) is -37.06
Alaunos Therapeutics Inc. ( TCRT ) Operating Income TTM ($MM) is -35.12
Alaunos Therapeutics Inc. ( TCRT ) Owners' Earnings Annual ($MM) is -42.28
Alaunos Therapeutics Inc. ( TCRT ) Current Price to Owners' Earnings ratio is -3.34
Alaunos Therapeutics Inc. ( TCRT ) EBITDA TTM ($MM) is -32.77
Alaunos Therapeutics Inc. ( TCRT ) EBITDA Margin is -109113.33%
Capital Allocation:
Alaunos Therapeutics Inc. ( TCRT ) has paid 0.00 dividends per share and bought back -24.947031 million shares in the past 12 months
Alaunos Therapeutics Inc. ( TCRT ) has reduced its debt by 48.1 million USD in the last 12 months
Capital Structure:
Alaunos Therapeutics Inc. ( TCRT ) Interest-bearing Debt ($MM) as of last quarter is 0
Alaunos Therapeutics Inc. ( TCRT ) Annual Working Capital Investments ($MM) are 20
Alaunos Therapeutics Inc. ( TCRT ) Book Value ($MM) as of last quarter is 13
Alaunos Therapeutics Inc. ( TCRT ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Alaunos Therapeutics Inc. ( TCRT ) has 11 million in cash on hand as of last quarter
Alaunos Therapeutics Inc. ( TCRT ) has 4 million of liabilities due within 12 months, and long term debt 10 as of last quarter
Alaunos Therapeutics Inc. ( TCRT ) has 240 common shares outstanding as of last quarter
Alaunos Therapeutics Inc. ( TCRT ) has 0 million USD of preferred stock value
Academic Scores:
Alaunos Therapeutics Inc. ( TCRT ) Altman Z-Score is -69.53 as of last quarter
Alaunos Therapeutics Inc. ( TCRT ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Alaunos Therapeutics Inc. ( TCRT ) largest shareholder is Northern Trust Corp owning 435575 shares at 0.02 ($MM) value
Kevin S Sr. Boyle(an insider) Sold 68014 shares of Alaunos Therapeutics Inc. ( TCRT ) for the amount of $9521.96 on 2023-09-01
4.40% of Alaunos Therapeutics Inc. ( TCRT ) is held by insiders, and 23.27% is held by institutions
Alaunos Therapeutics Inc. ( TCRT ) went public on 2005-08-24
Other Alaunos Therapeutics Inc. ( TCRT ) financial metrics:
FCF:-29.22
Unlevered Free Cash Flow:-112.75
EPS:-0.14
Operating Margin:-216600.00
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-243.91
Beta:0.21
Buffet's Owners Earnings:-42.28
Price to Owner's Earnings:-3.34
About Alaunos Therapeutics Inc. ( TCRT ) :
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.